|Articles|May 8, 2020
UHPLC analysis of challenging MAbs
This application note using YMC-Triart Bio C4 shows a robust separation at high temperatures of 3 commercially available MAbs: Ofatumumab, Palivizumab, and Panitumumab.
Related Content
Trending on LCGC International
1
How AI and Machine Learning Are Reshaping Separations Science at HPLC 2026
2
ASMS 2026 Award Winners Highlight the Future of Mass Spectrometry
3
GC-MS Detection of Microbes in Spacecraft Water
4
Best of the Week: Chromatography Methods, HPLC 2026 Previews, and More
5